Form 4: Phio Pharmaceuticals CEO Robert Bitterman Increases Stake in Company
SEC Form 4 Filing
Robert Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., recently purchased additional shares of the company's common stock.
Summary
- Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., has reported changes in his beneficial ownership of the company's stock.
- On May 21, 2025, Bitterman acquired 3,000 shares of common stock at a price of $1.77 per share.
- On May 22, 2025, he acquired an additional 1,200 shares at $1.7799 per share.
- Following these transactions, Bitterman's total direct ownership amounts to 23,649 shares, including shares underlying unvested restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the CEO is increasing his stake in the company, which is generally viewed favorably by investors.
Positives
- The CEO's purchase of additional shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Robert Bitterman purchased 3,000 shares of Phio Pharmaceuticals Corp. at $1.77 per share. |
| 05/22/2025 | Robert Bitterman purchased 1,200 shares of Phio Pharmaceuticals Corp. at $1.7799 per share. |
| 05/23/2025 | Date of signature for the Form 4 filing. |
Keywords
Phio Pharmaceuticals, PHIO, Robert Bitterman, insider trading, beneficial ownership, Form 4, stock purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.